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Abstract
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Testis development from an indifferent gonad is a critical step in embryogenesis. A hallmark of
testis differentiation is sex-specific vascularization which occurs as endothelial cells migrate from
the adjacent mesonephros into the testis to surround Sertoli-germ cell aggregates and induce
seminiferous cord formation. Many in vitro experiments have demonstrated that Vascular
Endothelial Growth Factor A (VEGFA) is a critical regulator of this process. Both inhibitors to
VEGFA signal transduction and excess VEGFA isoforms in testis organ cultures impaired
vascular development and seminiferous cord formation. However, in vivo models using mice
which selectively eliminated all VEGFA isoforms: in Sertoli and germ cells (pDmrt1Cre;Vegfa−/−); Sertoli and Leydig cells (Amhr2-Cre;Vegfa−/−) or Sertoli cells (Amh-Cre;Vegfa−/−
and Sry-Cre;Vegfa−/−) displayed testes with observably normal cords and vasculature at postnatal
day 0 and onwards. Embryonic testis development may be delayed in these mice; however, the
postnatal data indicate that VEGFA isoforms secreted from Sertoli, Leydig or germ cells are not
required for testis morphogenesis within the mouse. A Vegfa signal transduction array was
employed on postnatal testes from Sry-Cre;Vegfa−/− versus controls. Ptgs1 (Cox1) was the only
upregulated gene (5-fold). COX1 stimulates angiogenesis and upregulates, VEGFA, Prostaglandin
E2 (PGE2) and PGD2. Thus, other gene pathways may compensate for VEGFA loss, similar to
multiple independent mechanisms to maintain SOX9 expression. Multiple independent
mechanism that induce vascular development in the testis may contribute to and safeguard the sexspecific vasculature development responsible for inducing seminiferous cord formation, thus,
ensuring appropriate testis morphogenesis in the male.
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Many scientists have been investigating the factor or factors that are responsible for
inducing endothelial cell migration from the adjacent mesonephros into the developing
indifferent gonad for years. Endothelial cell migration and vascular development has been
demonstrated as one of the first steps for directing seminiferous cord formation and
initiating the testis differentiation pathway (Albrecht et al. 2000; Tilmann and Capel 1999).
Within this review we will discuss the reasoning behind investigating VEGFA, its ever
evolving complexity due to transcriptional and posttranslational regulation, and how it acts
on cells through multiple receptors and co-receptors as indicated mainly by rodent models
(Dehghanian et al. 2014; Qiu et al. 2009; Vieira et al. 2010). Since infertility in the human
male has been on the rise for almost 50 years (Carlsen et al. 1992, 1995; Carlsen et al. 1993;
Juul et al. 2014), more information into gonadal development and how fertility is affected
when mutations arise is critical to developing therapies for male related infertility issues. In
the last decade, there have also been interesting data to suggest that male infertility may be
associated with other health risks since men with subnormal sperm counts also had reduced
lifespans when evaluated between 1949 and 1985. This correlation between infertility and
shorter lifespans in men may be due to lifestyle and behavior choices, conditions in utero or
their genetic composition (Groos et al. 2006). There have been numerous incidences
reported in the scientific literature of prenatal exposure to compounds which alter gene
expression through epigenetic mechanisms and may affect reproduction and a host of other
critical functions (e.g. immune). Thus, prenatal or in utero conditions may be one avenue
that can be altered to increase reproductive function in men and also improve their lifelong
health status. Since an altered uterine environment may influence gene expression that is
necessary for testis development, any additional information on how testes develop may also
increase our ability to develop measures to diagnose male infertility disorders that arise
through prenatal programming or epigenetic causes.

How does a testis develop from an indifferent gonad?

Author Manuscript

The Sertoli cell expresses Sry (sex determining region of the Y chromosome, a gene that is
on the short arm of the Y chromosome) and is the first cell to differentiate in the testis
(Magre and Jost 1991). In the mouse, Sry is only briefly expressed (E10.5 to 12.5) and its
primary function is the upregulation of Sox9 (SRY-box 9) (Harley et al. 2003). Much of the
fate of the developing testis appears to be reliant on appropriate Sertoli cell differentiation
and on the ability of Sox9 expression to be maintained at high levels (Figure 1) thereby
leading to transcription of many genes to initiate testis development (Harley et al. 2003).
Furthermore, expression of Sox9 upregulates other genes such as Fibroblast Growth Factor 9
(Fgf9) which, in addition to cementing the testis differentiation pathway, may antagonize
genes such as Wingless type MMTV integration site family, member 4 (Wnt4), that if
overexpressed or not antagonized will enable development of the female pathway (Jameson
et al. 2012; Shan et al. 2009) (Figure 1).
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What is the origin of the Sertoli cell …a cell that is thought to direct testis
development?
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The precursors of the Sertoli cells are the early somatic progenitor cells which develop from
the coelomic epithelium. The coelomic epithelium is derived from the mesonephros and as it
differentiates it thickens, a phenomenon proposed to be due to gene expression of Sry. Many
different transcription factors are critical for the proper development of the gonadal
primordium which is enveloped by the coelomic epithelium such as EMX2 (empty spiracles
homeobox 2), WT1, NR5A1 (nuclear receptor subfamily 5, group A, member 1, formerly
SF1), LHX9 (LIM homeobox protein 9), GATA4 (GATA binding protein 4), ZFPM2/FOG2
(zinc finger protein, multitype 2) and others (Munger and Capel 2012; Wilhelm et al. 2007).
Both the thickening of the gonadal primordium to form the coelomic epithelium and the
expression of Sry is critical to allow Sertoli cells to develop. At least 20% of the Sertoli cells
need to express Sry in order for a testis to arise from the indifferent gonad (Burgoyne et al.
1995; Patek et al. 1991) (Figure 1). Furthermore, Sox9 has to be upregulated by E11.2
through the actions of Sry for testis development to continue; if Sox9 is not upregulated then
proliferation of the Sertoli cells will arrest along with testis development (Figure 1). In other
species such as domestic livestock, Sry is maintained much longer and appears to have other
functions (Daneau et al. 1996; Parma et al. 1999; Payen et al. 1996; Pelliniemi and Lauteala
1981).
Sox9

Author Manuscript

Originally Sox9 is expressed in the indifferent gonad by the pre-Sertoli/granulosa cells and is
transcribed at a very low copy number by SF1. When Sry is expressed, Sox9 is upregulated
in the testis and its expression is silenced in the ovary (Kobayashi et al. 2005). Because Sry
expression is short-lived, it is critical that other factors continue to upregulate and maintain
Sox9 expression (Figure 1). Sox9 induces the expression of Ffg9 and prostaglandin D2
synthase (Ptgds), in which the latter generates PGD2 (Wilhelm et al. 2007). One function of
both of these genes is to maintain upregulated Sox9 expression (Rossitto et al. 2015).
Furthermore, Sox9 also upregulates itself through two mechanisms. It binds its own
enhancer in a feed-forward fashion (Sekido and Lovell-Badge 2008) and by maintaining
upregulation of a transcription factor ER71/ETV2 (ets variant 2) which is initially increased
through Sry expression (DiTacchio et al. 2012).
FGF9

Author Manuscript

Elimination of FGF9 or its receptor FGFR2 (fibroblast growth factor receptor 2) can cause
male-to-female sex reversal given that FGF9 down regulates or suppresses the Wnt pathway
which would otherwise promote female gonadal development (Bagheri-Fam et al. 2008;
Colvin et al. 2001; Jameson et al. 2012; Jeays-Ward et al. 2003; Siggers et al. 2014; Vainio
et al. 1999) (Figure 1). Wnt4 knockout mice are sex-reversed similarly to knockouts of
FGF9 (Shan et al. 2009). It was determined that FGF9 antagonizes the actions of WNT4 and
thus prevents the ovarian pathway and allows for seminiferous cords to develop (Jameson et
al. 2012; Kim et al. 2006). FGF9 also is critical for Sertoli cell proliferation necessary to
provide enough Sertoli cells to differentiate to form clusters with germ cells.
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The gene encoding Ptgds (Lipocalin-type prostaglandin D2 synthase), an enzyme that
produces PGD2, was identified in 2002 to be initially expressed in the developing urogenital
ridges and later in Sertoli cells and prospermatogonia at around E11.5 (Adams and McLaren
2002) (Figure 1). Expression of the Ptgds gene in the developing testis was noted to be in a
similar pattern as both Sry and Sox9 starting at the center and moving to the anterior poles in
the developing testis (Wilhelm et al. 2007). Furthermore, expression of L-PGDS protein was
present in E12.5 male gonads in both Sertoli and germ cells (Moniot et al. 2009) that it is
regulated upstream through either COX1 (cyclooxygenase 1) or COX2 pathways (Rossitto
et al. 2015). However, neither male Cox2- nor Cox1- knockout mice are infertile; thus, there
may be multiple ways to promote production of L-PGDS in order to have a sufficient
quantity of PGD2 (Gerena et al. 2000a; Gerena et al. 2000b). PTGDS is up-regulated by
Sox9 but not Sry (Wilhelm et al. 2007). PGD2 acts through its receptor, DP1 (prostaglandin
D2 receptor 1) in Sertoli cells, to translocate the cytoplasmic SOX9 protein, to the nucleus to
influence gene expression.
How is PGD2 regulated?

Author Manuscript

Many endocrine disruptors such as phthalates, bisphenol and NSAIDS that inhibit COX
activities also reduce PGD2 production as demonstrated in a mouse Sertoli cell line and fetal
testis cultures (Kristensen et al. 2011a; Kristensen et al. 2012; Kristensen et al. 2011b).
Thus, it appears that the COX signaling pathway is involved and potentially downstream of
SOX9 to induce expression of PGD2. In addition to PGD2, COX1 and 2 can stimulate
upregulation of other prostaglandins such as PGE2 which is proangiogenic and can further
enhance the expression of VEGFA (Cheng et al. 1998; Pai et al. 2001). Furthermore, there
appears to be a positive feedback pathway between COX2 and VEGFA with each of them
increasing the other's expression as well as VEGFA upregulating upstream factors in the
arachidonic pathway to further enhance COX2 activity. COX1 is thought to be constitutively
expressed while most of the effects of hypoxia and VEGFA may be through stimulation of
the inducible COX2 (Iniguez et al. 2003) (Fig. 2). Since, angiogenic inhibitors do not appear
to inhibit COX1; it is possible that the constitutively-expressed COX1 may safeguard some
function of angiogenesis within the developing testes.

Mesonephric cell migration directs testis development: are the migrating
mesonephric cells peritubular myoid cells or endothelial cells?

Author Manuscript

As Sertoli cells differentiate and establish intimate contact with germ cells, they form
clusters with germ cells aptly named Sertoli-germ cell clusters (Tesarik et al. 2002). Germ
cells are of extragonadal origin and migrate to the indifferent gonad prior to Sertoli cell
differentiation (Mintz and Russell 1957; Ozdzenski 1969). Germ cells do not appear to
induce seminiferous cord formation since cord formation still occurs in the testis of c-Kit
(kit oncogene, also known as c-Kit) knockout despite a lack of primordial germ cells
migration to and colonization of the indifferent gonad (Nocka et al. 1989; Runyan et al.
2006).
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Very elegant studies have demonstrated that mesonephric cells migrating from the
mesonephros are necessary for cord formation and later that the developing testis from an
indifferent gonad directs mesonephric cell migration (Buehr et al. 1993). This migration can
even pass through an ovary inserted between the mesonephros and the developing testis
(Tilmann and Capel 1999). Initially the migrating cells were thought to be pre-peritubular
myoid cells since that cell type is what forms around seminiferous cords and aids later in
development of the blood-testis barrier (Buehr et al. 1993). However, others have
demonstrated that all cells that migrated are endothelial cells (Combes et al. 2009; Cool et
al. 2008).
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Since the Sertoli cells are the first cell to differentiate in the testis (Magre and Jost 1991),
they were thought to be the catalyst for induction of endothelial cell migration via secretion
of factors that serve as chemoattractants for mesonephric cells. Later it was determined that
mesonephric cell migration not only directs seminiferous cord formation but also may
induce proliferation of the somatic cells up to a certain threshold to restrict their number.
Early studies identified factors that had receptors within PTM cells such as neurotrophins
(NT) (Levine et al. 2000) and PDGF's (Puglianiello et al. 2004). The low affinity receptor
for the neurotrophins, NGFR (nerve growth factor receptor), is expressed in cells which
appear to migrate from the mesonephros into the differentiating testis and by P0 it is only
expressed in a thin layer of cells which appear to have differentiated into the PTM layer that
surrounds each seminiferous cord (Russo et al. 1999). Other experiments demonstrated that
NT3 may be involved in mesonephric cell migration and Trk knockout mice contained fewer
cords within the testis than wild type mice, in addition to some fused or odd shaped cords
(Cupp et al. 2002; Cupp et al. 2003).
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The focus then became the endothelial cells because most of the cells that migrate from the
mesonephros contained endothelial cell markers. In addition, sex-specific vasculature
develops in the testis and ovary with large differences noted in vascular reorganization and
origin in the testis compared to the ovary (Bott et al. 2010; Combes et al. 2009; Cool et al.
2008). It was postulated Sertoli cells produced angiogenic or vascular-specific factors to
induce endothelial cell migration and cause sex-specific vascular development and
seminiferous cord formation (Bott et al. 2010; Tilmann and Capel 1999). Again the question
was what angiogenic or vascular-specific factors were produced by the Sertoli cells around
the time of sex-specific vasculature development and seminiferous cord formation?
What composes the VEGFA ligand receptor family and how does VEGFA signal through its
receptors and co-receptors?

Author Manuscript

The VEGF family was a logical growth factor family to evaluate its involvement in
endothelial cell migration within the developing testis due to its ability to stimulate
endothelial cell migration, survival, proliferation and differentiation to initiate
vasculogenesis and angiogenesis within developing organs and tumors (Ferrara et al. 2003;
Lee et al. 2015). The VEGF family is composed of VEGFA, VEGFB, VEGFC, VEGFD,
and PGF (Placental Growth Factor, previously known as PlGF). VEGFA is the most studied
family member and is critical for angiogenic processes (Ferrara et al. 2003). Even the
disruption of one allele (heterozygotic deletion) causes embryonic lethality between E11 and
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E12. Since neovascularization does not occur in these mice, this suggests that the embryonic
lethality is due to a lack of oxygen and nutrients delivery to organs and that VEGFA is
critical for most organ functions (Ferrara et al. 1996).

What are the receptors to which VEGFA binds?

Author Manuscript

VEGFA binds to two different tyrosine kinase receptors: kinase insert domain protein
receptor (KDR also known as VEGFR2 and FLK1), and FMS-like tyrosine kinase 1 (FLT1,
also known as VEGFR1) (Ferrara et al. 2003). Both the KDR and the FLT1 receptors
contain an extracellular domain comprised of seven immunoglobulin-like (Ig-like) folds (Fig
3). The function of the Ig-like folds were determined through mutation experiments
indicating the VEGFA high affinity ligand binding domain is within the 2nd and 3rd folds
while the 1st and 4th Ig-like fold regulate the ability for the ligand to bind and the receptor to
dimerize (Davis-Smyth et al. 1998; Fuh et al. 1998; Shinkai et al. 1998; Vieira et al. 2010).
The KDR receptor is the primary receptor that VEGFA signals through (Cunningham et al.
1999; Kroll and Waltenberger 1997; Seetharam et al. 1995; Waltenberger et al. 1994;
Wheeler-Jones et al. 1997). This is mainly due to the observation that the tyrosine
phosphorylation sites on the FLT1 receptor (in the regulatory juxtamembrane domain and
five within the C-terminus; Figure 3) are never phosphorylated when the VEGFA ligand
binds endothelial cells.
FLT-1 receptor—why is it called the decoy receptor?
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FLT1 has higher affinity for VEGFA than KDR (Gille et al. 2001; Olofsson et al. 1998;
Waltenberger et al. 1994). Since there was no phosphorylation of its tyrosine residues the
main function of this receptor was thought to be to function as a decoy receptor for VEGFA
and, thus, to inhibit VEGFA-KDR ligand-receptor interactions and subsequent signal
transduction. Presumably this was to allow for inhibition of vascularization of tissues
(Ferrara 2000; Zachary and Gliki 2001). This is supported by a study demonstrating that
FLT1/VEGFR1 knockout mice that die at E8 and E9 is due to a failure of endothelial cells to
assemble into a vasculature circuit (Fong et al. 1995). Since most KDR-mediated VEGFA
binding results in vascularization of tissues, an increase in FLT1 production to inhibit
binding to KDR may be a method to regulate vascularization. Recent reports have also
suggested that FLT1 may prevent endothelial cell apoptosis and thus is a potential survival
factor (Vieira et al. 2010). This may be due to FLT1 but not KDR being regulated by
hypoxia. Within the promoter region of the FLT1 receptor is a binding site for hypoxia
inducible factor 1, alpha subunit (HIF1A) (Gerber et al. 1997). Thus, FLT1 expression along
with upregulation of VEGFA through hypoxia (since there is a HIF1A promoter site in the
VEGFA promoter, as well) may allow for survival of these cells and stimulation of some
sort of vascular growth to provide oxygen to the tissue. Due to alternative splicing, FLT1 is
not only present in a membrane-bound form but also has a soluble form (sFLT1) that acts
similarly to binding proteins. Thus this soluble form may also act as a decoy receptor to
sequester VEGFA away from KDR (Kearney et al. 2004). An increase in sFLT1 has been
demonstrated to occur in pathological states such as preeclampsia (Autiero et al. 2003;
Hiratsuka et al. 2001). Thus, regulation of the soluble as well as membrane forms of FLT1
are critical to allow for appropriate vascularization of tissues.
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FLT1 contains several potential tyrosine autophosphorylation sites in the c-terminus and
also juxtamembrane transmembrane domain. These sites are suppressed by a repressor
element located in the juxtamembrane domain which inhibits the phosphorylation of these
tyrosine residues after VEGFA binding (Gille et al. 2000). However in monocytes and
macrophages this repression is not present and there is no information to suggest how this
occurs other than secretion of factors that relieve this inhibition. Thus, in these particular
cell types, FLT1 can recruit several different accessory proteins such as protein kinases
related to SRC (Rous sarcoma oncogene), FYN (fyn proto-oncogene) and YES1
(Yamaguchi sarcoma viral (v-yes) oncogene homolog 1) (Chou et al. 2002).
Does FLT-1 signal in the somatic cells of the testis or is it repressed similarly to
endothelial cells?
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Caires et al. (2012) demonstrated that there was increased phosphorylation of tyrosine (Y)
1333 within the FLT1 receptor in somatic cells at postnatal day 3 (P3) in mice compared to
activation in gonocytes, Sertoli, and Leydig cells at P1 (Caires et al. 2012). Also inhibitors
which blocked both FLT1 and KDR simultaneously were effective in testis organ cultures in
inhibiting both sex-specific vascular development as well as seminiferous cord formation
(Bott et al. 2006) (Table 1). To our knowledge, no experiments have been conducted to
determine if FLT1 signals in the somatic or germ cells of the testis early in development, but
it is possible that this occurs. Since FLT1 is not present until after seminiferous cord
formation in the testis (Bott et al. 2006) it may not be critical. However, since FLT1 can be
upregulated by hypoxia, it may be a failsafe mechanism to initiate neovascularization in
some tissues outside the testis where VEGFA or KDR are limiting and vascularization of the
tissue is critical for survival.
Why is KDR thought to be the primary receptor through which VEGFA signals?
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In contrast to FLT1, the KDR receptor is autophosphorylated on several tyrosine residues
after ligand binding and receptor dimerization, that have been depicted in the human in the
kinase insert domain Figure 3): Y951 (Y949 mouse); in the tyrosine kinase domain: Y1054
and Y1059 (Y1053, Y1057 mouse); and in the C-terminal domain Y1175 and Y1214
(Y1173,Y1212 mouse) (Eliceiri et al. 1999; Vieira et al. 2010; Werdich and Penn 2005).
Most phosphorylation experiments have been conducted in endothelial cells; however, these
tyrosine residues recruit different downstream signaling molecules when phosphorylated to
induce different events (Eliceiri et al. 1999; Vieira et al. 2010; Werdich and Penn 2005).
This autophosphorylation is actually a form of trans-phosphorylation that is prevented until
the conformation of KDR changes following VEGFA binding and the receptor monomers
come into close juxtaposition (Tao et al. 2001).
KDR phosphotyrosines such as Y951 and Y1175 are recognized by SRC family kinases
which have been shown to modulate endothelial proliferation and migration (Eliceiri et al.
1999; Vieira et al. 2010; Werdich and Penn 2005). Many different knockout mouse models
have been developed which mutate or eliminate these tyrosine residues in order to determine
their function (Figure 3). The Y951 phosphotyrosine works through TSAd (T Cell–Specific
Adapter) and Src and is involved in endothelial cell permeability and migration while both
J Endocrinol. Author manuscript; available in PMC 2016 October 01.
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Y1175 and Y1214 also are involved in endothelial cell proliferation or migration as
indicated through mutation experiments (Rajagopal et al. 1999). The tyrosine residue Y1214
works through growth factor receptor bound protein 2 (GRB2) and has been implicated to be
in control of actin reorganization and cell migration which is thought to occur through
CDC42 (cell division cycle 42) and MAPK (mitogen-activated protein kinase) cascades
(Lamalice et al. 2004) (Figure 3). Many different signal transduction pathways occur
through Y1175: activation of phospholipase C (PLC) gamma, protein kinase C (PKC), and
MAPK to cause proliferation. Src is recruited to this residue as well as SHB (src homology 2
domain-containing transforming protein B) which will allow for migration, survival and
permeability of endothelial cells (Aouadi et al. 2006). SHB controls endothelial cell
migration through focal adhesion kinase (FAK) in a PI3 (phosphoinositide-3) kinasemediated pathway (Kriz et al. 2006) (Figure 3). Caires et al., 2012 demonstrated that during
early postnatal periods, the 1054 phosphotyrosine is autophosphorylated (1053 in the
mouse), and VEGFA signaling through KDR is clearly present in both Sertoli, Leydig and
germ cells at different stages of early postnatal development (Caires et al. 2012). Thus, these
pathways should be explored to determine which phosphotyrosines are specifically
necessary for VEGFA's function within the developing testis during sex-specific
vascularization.
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KDR is critical to embryogenesis since KDR knockout mice die at E8.5 to E9.5 (Shalaby et
al. 1995). These embryos lack blood island formation in the yolk sac and experience a
dramatic reduction in haematopoetic precursors, suggesting KDR is necessary for
vasculogenesis. Furthermore, since they mark the early haemangioblast that differentiates
into endothelial cells as well as haematopoeitic progenitors, it is possible that KDR is also
involved in haematopoiesis as well as vascularization of tissues through endothelial cells
(Ciau-Uitz et al. 2013; Jaffredo et al. 2005; Medvinsky et al. 2011; Murray 1932).
Interestingly, mice carrying only a single amino acid mutation that prevents KDR activation
of ERK 1/2 die in utero due to vascular defects suggesting that phosphorylation of this
receptor is critical to multiple vasculature functions within the developing embryo (Sakurai
et al. 2005).

What is the expression pattern of the KDR, FLT-1 receptors during testis
development?
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Expression of KDR occurs relatively early and marks sex-specific vascular development in
both the testis and ovary as indicated in KDR-LacZ transgenic mice (Bott et al. 2010).
Expression of KDR is apparent on cells which appear to be migrating into the testis at the
time of sex-specific migration. Later as seminiferous cords form and are apparent, these
KDR-LacZ marked cells are present around the seminiferous cords (Bott et al. 2010; Bott et
al. 2006). Since the KDR receptor signals through tyrosine kinase autophosphorylation,
several different tyrosine kinase inhibitors were utilized to determine how this may affect
seminiferous cord formation and sex-specific vascular development in testis organ cultures.
In rat testis organ cultures, VEGFRTKI (a tyrosine kinase inhibitor specific to KDR and
FLT1) inhibited sex-specific vascular development (reduction by 90% in all vascular
development in the testis; Table 1) and seminiferous cord formation (Bott et al. 2006). In
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addition, a KDR specific inhibitor, SU1498, reduced vascular development by 90% and
perturbed cord formation (Bott et al. 2006) (Table 1). Furthermore, KDR-LacZ-positive
staining in mouse testis organ cultures was reduced at day 1, 2 and 3 of culture by 66%, 90%
and 99%, respectively, when they were treated with VEGFR-TKI. These data suggest that
endothelial cell migration, proliferation and survival may have been blocked which
prevented the testis from being vascularized (Bott et al. 2010). Thus, it does appear that
KDR-LacZ marked cells migrate into the testis and can be inhibited by a specific VEGFR
inhibitor. Other inhibitors to PI3 kinase have also been demonstrated to detriment sexspecific vascular development but only reduce vascular development by 56% (Bott et al.
2006) despite perturbing seminiferous cord formation (Bott et al. 2006; Uzumcu et al.
2002b) (Table 1). Inhibition of the MAPK pathway also alters cord formation (Uzumcu et
al. 2002b), but vascular development was not evaluated. Since VEGFA signals through
KDR to stimulate both MAPK and PI3 kinase, these data support of a role for VEGFA in
regulating sex-specific vascular development within the developing rodent testis.
FLT1, however, is not expressed in the rodent until after cord formation in the male (Bott et
al. 2006) while both KDR and FLT1 are expressed early in the ovary (McFee et al. 2009).
KDR, FLT1 and VEGFA are expressed by oocyte cysts, oocytes and pregranulosa/granulosa
cells of all stage follicles at P0, P3, and P10 as well as in theca cells of late antral follicles
(McFee et al. 2009). There is a possibility that FLT1 expression in the ovary sequesters the
VEGFA ligand and prevents it from binding to KDR and to block endothelial cell migration
within the ovary at the time sex-specific vascular development occurs in the testis.

What are the alternatively spliced products of VEGFA and what are their
function(s)?
Author Manuscript
Author Manuscript

Of the 25,000 genes in the human genome, at least 70% are alternatively spliced, and
abnormal alternative splicing can be correlated with a large number of human genetic
deficiencies (Black 2003; Matlin et al. 2005). VEGFA is transcribed from a single gene that
is alternatively spliced into many different isoforms depending on the cell type of interest.
Many VEGFA isoforms have been identified (VEGFA111, 121, 165, 148, 145, 183, 189,
206), and the most common VEGFA isoforms that have been studied are human angiogenic
VEGFA206, VEGFA189, VEGFA165, VEGFA145 and VEGFA121 (Figure 4). The
numbers on the isoforms denote the number of amino acids and in the rodent there is one
less amino acid for each isoform: VEGFA205, VEGFA188, VEGFA164, VEGFA144,
VEGFA120 (Fig. 4). For this review we will utilize the rodent VEGFA isoforms since much
of the research discussed will be in the rodent (Giacca 2010; Hoeben et al. 2004; Kajdaniuk
et al. 2011).
Within the Vegfa gene, there are 8 exons and all VEGFA isoforms contain exons 1–5 except
for a newly identified isoform, VEGFA111, which contains only 1–4 and exon 8. A signal
peptide is located within exons 1 and 2 and upon cleavage, produces a mature peptide. In
exon 5, there are cleavage sites for plasmin and matrix metalloproteinases. Since
VEGFA111 does not contain exon 5, this isoform is resistant to their cleavage and is a
critical compound utilized in therapies for different cell ischemia (Houck et al. 1991;
Mineur et al. 2007). Exons 6a and 7 encode heparin binding domains and isoforms
J Endocrinol. Author manuscript; available in PMC 2016 October 01.
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containing these exons bind to cell surfaces and are not as diffusible as isoforms that do not
contain these exons. Also contained within exons 6a and 7 are a neuropilin binding site
(Keyt et al. 1996; Lee et al. 2005). The 5' untranslated region (UTR) of Vegfa is
approximately 1038 nucleotides in humans and consists of 3 CUG start codons, an AUG
initiation codon and two internal ribosome entry sites (IRESes) which can control VEGFA
translation. The 3'UTR consists of polyadenylation signals and AU-rich response element
which allows for response to stabilizing and destabilizing mRNAs (Konopatskaya et al.
2006; Seifi et al. 2012) (Figure 4).

Author Manuscript

The VEGFA205 isoform contains all exons and is proposed to bind more tightly to
extracellular matrix proteins in addition to being greater in amino acid number than other
isoforms. The VEGFA188 isoform has 2 heparin binding domains, remains relatively close
to the cell in which it was secreted, and acts locally to support branching of vasculature. The
VEGFA164 isoform contains only one heparin binding domain and has intermediate
diffusibility, and has a prominent role in the formation of large blood vessels. The
VEGFA120 isoforms lacks a heparin binding domain, is the most diffusible, and can migrate
the farthest from the secreted cells. The differences in diffusibility of these different VEGFA
isoforms allow for the development of a chemoattractant gradient which induces endothelial
cells to migrate toward cells which produce VEGFA (Carmeliet and Collen 1999; Ferrara
2010; Grunstein et al. 2000; Krilleke et al. 2009; Simons 2007; Veikkola and Alitalo 1999).

What is the expression and potential actions of VEGFA isoforms in the
developing testis?

Author Manuscript

The presence of multiple VEGFA isoforms differing in number of amino acids was
identified in the developing rat testis: VEGFA120, 164 and 188 (Bott et al. 2006) (Figure 4).
Using a pan antibody to all VEGFA isoforms it was demonstrated that protein for the panVEGFA (which detects both angiogenic and antiangiogenic isoforms) was lower at E13 and
increased by P4. Sertoli cells had the greatest abundance of panVEGFA expression around
the time of cord formation (Bott et al. 2006).
It does not appear that a chemoattractant gradient for VEGFA exists in the ovary around the
time of seminiferous cord formation in the rat testis because the only VEGFA isoforms that
are present are VEGFA164 and VEGFA120. The two higher molecular weight VEGFA
isoforms VEGFA188 and VEGFA205 have not been detected (McFee et al. 2009); thus, we
hypothesize that there is no viable chemoattractant gradient to allow for endothelial cell
migration from the mesonephros into the ovary.

Author Manuscript

Furthermore, treatment of E13 rat testis organ cultures with VEGFA120 and VEGFA164
causes formation of altered (absent, swollen and misshaped) seminiferous cords as well as
dramatically increased vascular density (160 and 157% that of controls; Table 2). Thus,
excess VEGFA angiogenic isoforms 164 and 120 can elicit detrimental effects on testis
development and potentially have as dramatic effects as inhibition of VEGFA signal
transduction discussed earlier (Bott et al. 2006) (Table 1). All of these VEGFA angiogenic
isoforms have been shown to bind both KDR and NRP1, but even though there may be
binding of VEGFA120 (which does not have a heparin and thus NRP1 binding domain) to
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NRP-1, the bridging to KDR does not appear to occur. This may affect the amplification of
the VEGFA120 signal transduction as well as the recycling of the KDR receptor within the
cell (Pan et al. 2007).
VEGFA antiangiogenic isoforms

Author Manuscript

In 2002, a second set of sister isoforms was identified through alternative splicing and
replacement of exon 8a with 8b (Bates et al. 2002) (Figure 4). These sister VEGFA isoforms
were considered inhibitory to angiogenic functions and were labeled antiangiogenic VEGFA
isoforms. Several antiangiogenic isoforms have been identified- VEGFA212b,
VEGFA145b, 183b, 189b, 165b, and 121b (Bates et al. 2002; Dehghanian et al. 2014;
Woolard et al. 2004) (Fig. 3). VEGF165b is normally expressed in tissues but is downregulated in prostate and renal tumors suggesting a role in inhibiting the vasculogenic and
angiogenic actions of other VEGF isoforms (Bates et al. 2002; Woolard et al. 2004). Several
reports have suggested that these antiangiogenic VEGFA isoforms may function to
antagonize angiogenic VEGFA isoform functions through binding of the receptors and
preventing angiogenic isoforms from binding (Qiu et al. 2009).
Much controversy has ensued over whether these “b” isoforms exist or whether they are
artifacts of alternative splicing (Harris et al. 2012). While it is true that determining the
difference in the angiogenic vs the antiangiogenic isoforms has been a challenge, data from
our laboratory and others using either recombinant angiogenic or antiangiogenic VEGFA
isoforms has resulted in very different outcomes that demonstrate the existence of divergent
VEGFA isoforms (Artac et al. 2009; Baltes-Breitwisch et al. 2010; Bates et al. 2013; Caires
et al. 2012; McFee et al. 2009).
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For instance, the VEGFAxxxb antibody (detects all antiangiogenic isoforms but sold as
antiVEGFA165b) detected antiangiogenic isoforms in germ cells from E14 to E16 with
expression in the interstitium by P0 (Baltes-Breitwisch et al. 2010). This result in expression
was very different from the panVEGFA antibody which detects all VEGFA isoforms where
expression was detected in Sertoli cells and potentially some germ and Leydig cells (Bott et
al. 2006). When we used this antibody to the exon 8b (which will neutralize antiangiogenic
isoforms and allow endogenous VEGFA angiogenic isoforms to bind) on E13 rat testis
organ cultures we had similar results as treating with recombinant VEGFA120 or
VEGFA164 (Table 2). Either dose of VEGFAxxxb antibody, dramatically increased
vascular density (195%) versus control testes compared to increases in vascular density of
160% (VEGFA164) or 157% (VEGFA120) (Table 2). In addition, the seminiferous cords
were swollen, perturbed, or misshapen which was very similar to what was seen with the
recombinant angiogenic VEGFA isoforms treatment (Baltes-Breitwisch et al. 2010). Thus, it
appears that removal of the antiangiogenic isoforms increases the amount of endogenous
angiogenic VEGFA isoforms that can bind to the VEGFA receptors and elicit similar effects
to treatments with recombinant angiogenic VEGFA isoforms. Thus, from our data and
others we would suggest that the antiangiogenic isoforms do exist whether they are
produced from alternative splicing or through other recently identified means.
Whole testis western blots conducted with the antiangiogenic VEGFAxxxb antibody did not
demonstrate major differences in the levels of antiangiogenic VEGFA isoform abundance
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during early testis development, but the immunohistochemistry clearly indicated that
VEGFAxxxb isoforms were not expressed in somatic cells and only in germ cells during
early testis development (Baltes-Breitwisch et al. 2010). Quantitiative PCR demonstrated a
5-fold greater abundance of antiangiogenic VEGFA165b in the ovary vs the testis at E13
which indicated that antiangiogenic isoforms may be inhibiting angiogenic VEGFA isoform
functions related to endothelial cell migration or development of chemoattractant gradients.
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Recently, a paper was published in Cell (Eswarappa et al. 2014) which identified yet another
antiangiogenic VEGFA isoform in human and bovine endothelial cell lines that is produced
by programmed translational readthrough which has a cis-acting element in the Vegfa 3'UTR
that serves a dual function (Figure 4). It can encode the shortened peptide but can also direct
the programmed readthrough by decoding the UGA stop codon (Figure 4). A heterogeneous
nuclear ribonucleoprotein (hnRNP) A2/B1 binds this element and promotes readthrough,
producing a product that has exon 8a and 8b. This product acts similarly to antiangiogenic
isoforms and is down regulated in certain cancers (Eswarappa et al. 2014). The authors of
this paper have named this isoform VEGFAx. The Ax is named for the Ax element which is
a 62 nucleotide extension inserted between the 2 stop codons which normally would confer
either angiogenic (with exon 8a) or antiangiogenic isoforms (with exon 8b; Figure 4). Thus,
the binding protein hnRNP A2/B1 binds the A2/B1 response element (A2RE) in the Ax
element and positively regulates VEGFA readthrough. This finding is exciting since this is
the first time that a trans factor has been identified that regulates translational readthrough.
Furthermore, most translational readthrough was only thought to occur in evolutionarily
lower-ordered species such as Drosophila, viruses, etc. Since the VEGFAx protein acts like
an antiangiogenic isoform, more experiments are needed to determine if this protein is
present only in certain cell types that produce this trans-factor hnRNP A2/B1 or whether
they are ubiquitous (Eswarappa et al. 2014).

Author Manuscript

In experiments where VEGFA isoforms have been subcloned from primary bovine
granulosa cells, some VEGFA isoform PCR subcloned products contained both exon 8a and
8b suggesting that there is a readthrough product in the bovine (McFee, Spuri Gomes, Artac,
Summers, Pohlmeier, Brauer, Kurz, Cushman, Wood and Cupp, unpublished observations)
(Figure 4). This was not the case for subcloned VEGFA from rat granulosa or Sertoli cells.
In addition, there were subcloned products which only contained either the 8a or 8b in the
bovine and rat without the Ax product. Thus, within each cell, the necessary machinerywhether it is splicing proteins or proteins that allow for programmed read through- may be
present at critical physiological states to ensure the appropriate balance of VEGFA
angiogenic and antiangiogenic isoforms. More experiments are needed to ensure the
VEGFAx product exists; however, if these data are confirmed there could be an
evolutionary change in insertion of the Ax sequence (62 nucleotides) which may provide
different functions in higher evolved mammals.

Are there differences in VEGFA angiogenic and antiangiogenic isoform
actions on their receptors?
Neuropilin 1 (NRP1) was originally identified as a receptor in the nervous system and was
found to modulate semaphorin signals (He and Tessier-Lavigne 1997; Takahashi et al. 1998)
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and direct neuronal axon guidance. However, NRP1 has also been found to be critical for
vascular development in cooperation with the VEGFA angiogenic isoforms in many
different angiogenic processes (Kawasaki et al. 1999). NRP1 knockout mice die between
10.5 and 12.5 and have vasculature development defects as well as heart and neural defects
suggesting that NRP1 is critical for both vascular and neuronal development (Kawasaki et
al. 1999). NRP1 can bind to semaphorins instead of VEGFA and this impairs endothelial
cell migration (Miao et al. 1999). Semaphorins are present within the testis and appear to be
secreted by Sertoli cells (Perala et al. 2005). Whether semaphorins are antagonistic to
vascular development within the testis this is yet unknown. Alternatively, NRP/VEGFA
complexes binding to FLT1 can also prevent endothelial cell migration and vascular
development (Miao et al. 1999) so there are potentially many check points that are present
within the testis to prevent over-vascularization to ensure development of the seminiferous
cords.
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NRP1 is a co-receptor to VEGFA but it does not bind either KDR or FLT-1 but instead
binds to a region on the VEGFA ligand (Figure 4). Because KDR lacks a PDZ-binding
domain it cannot interact with a PDZ protein synectin (which is also called GIPC1 or NIP).
NRP1 has a SEA motif which allows for PDZ protein synectin binding. KDR can utilize
NRP1 bound to VEGFA angiogenic isoforms as a bridge to enhance signal transduction and
also allow for appropriate trafficking of NRP1 within the cell to allow for receptor recycling
(Cai and Reed 1999; Wang et al. 2006).
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Due to the presence of exon 8b rather than 8a, the VEGFA antiangiogenic isoforms cannot
bind NRP1 since much of their binding region is within the exon 8a region. Thus,
elimination of NRP1 or overexpression will only affect angiogenic VEGFA isoform
functions (Kawamura et al. 2008). When NRP1 is bound to VEGFA164 and then they bind
and signal through KDR, this causes the KDR receptor to be recycled through Rab5, Rab4
and Rab11 vesicles. However, antiangiogenic VEGFA cannot bind NRP1. Therefore, when
VEGFA164b binds to KDR, KDR bypasses the Rab11 vesicles in cells and is routed to the
Rab7 vessicles which moves KDR to the degradation pathway. Also, if the SEA binding
motif for synectin is deleted from NRP1, will attenuate the receptor-ligand signal
amplification since the SEA carboxyterminal domain of NRP1 mediates the events to allow
for KDR recycling via Rab11 positive endosomes (Ballmer-Hofer et al. 2011).

How are NRP1 receptors expressed and regulated within the gonad?
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NRP1 receptors are present early in both the testis and ovary (Walker, Lu, Clopton, and
Cupp, unpublished observations) and have the potential to interact with VEGFA and present
both to KDR and FLT1. Because FLT1 is present during gonadal development, it is possible
that FLT1 is sequestering NRP1 and VEGFA away from KDR and limiting signal
transduction and subsequent endothelial cell migration in the ovary (Baltes-Breitwisch et al.
2010). An inhibitor to the NRP1 co-receptor, Je-11, was utilized to determine its effects on
E13 rat testis organ cultures. Initially this inhibitor was thought to be specific only to KDR
but later was found to inhibit only NRP1. This inhibitor caused a 42% reduction in vascular
development with a less defined coelomic vessel and cords that were either not present or
perturbed (Bott et al. 2006) (Table 1). This inhibitor was not as effective as the inhibitors
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either to KDR alone or to KDR and FLT1 simultaneously, suggesting that KDR can signal
and cause vascular development independent of NRP1 which has been demonstrated in
many different endothelial cells and systems with vascularization (Vieira et al. 2010).
However these results do demonstrate its role in enhancement of KDR signaling. Through
altered receptor recycling we can envision a function for NRP1 in development of
endothelial cell migration, arteriogenesis–mainly the coelomic vessel-, and induction of cord
formation within the developing testis.

What happens in vivo when VEGFA isoforms are eliminated in somatic and
germ cells during testis development?
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In order to determine if VEGFA was critical for testis development multiple conditional
knockout mouse lines were developed to eliminate all VEGFA isoforms in: Sertoli and some
germ cells (pDmrt1-Cre;Vegfa−/−); Sertoli and Leydig cells (Amhr2-Cre;Vegfa−/−); and
Sertoli cells only (Amh-Cre;Vegfa−/− and Sry-Cre;Vegfa−/−). To date, testes formed
normally in these male mice by P0 and there do not appear to be differences in vasculature
based on published work from our laboratory (Lu et al. 2013) as well as on unpublished
results (Sargent, Spuri Gomes, Essink, Kurz, Pohlmeier, Ferrara, Bouma, McLean, and
Cupp; Sargent, Essink, Bremer, Pohlmeier, and Cupp, unpublished observations) in VEGFA
or NRP1 knockout versus the control testes. Instead of effects on vasculature, our laboratory
has demonstrated effects on male fertility through altered spermatogonial stem cell
maintenance (Lu et al. 2013). Furthermore, using different VEGFA angiogenic and
antiangiogenic isoforms we also have demonstrated different effects on number of
spermatogonial stem cells in endogenously depleted recipients (Caires et al. 2012). It is
possible that vascular development in these males is delayed embryonically; however, what
we can state is that VEGFA does not appear to be required for testis development since
these testes contain a coelomic vessel and seminiferous cords that form into seminiferous
tubules. Furthermore, from the P0 time period the only phenotype that appears to be
abnormal is the number of germ cells at different stages and the number of undifferentiated
spermatogonia leading to differences in number of sperm (Lu et al. 2013). These findings
were echoed by measurement of VEGFA in roe deer where expression correlated more with
transition of germ cell stages than with testis microvasculature (Wagener et al. 2010). When
Vegfa was in control of and overexpressed by the MMTV promoter in mice, the animals
were infertile. This infertility was thought to result, in part, from testicular spermatogenic
cell arrest which further demonstrates non-endothelial effects of VEGFA in the testis
(Korpelainen et al. 1998).
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Due to our conditional knockout mouse data it does not appear that VEGFA is absolutely
required for normal testis development. In many ways this makes sense because throughout
testis development there are multiple factors that upregulate expression of genes to ensure
proper differentiation of a testis. NR5A1 induces initial expression of Sox9 which is then
upregulated by SRY and SOX9 (Sekido and Lovell-Badge 2008) and SOX9 not only
upregulates FGF9 and PTGS but it also upregulates itself (DiTacchio et al. 2012). A role of
both PTGS and FGF9 is to continually provide sustained expression of SOX9 (Rossitto et al.
2015) (Fig. 1). Thus, since sex-specific vascular development drives seminiferous cord
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formation it would logically follow that there are multiple mechanism which allow for this
to happen– potentially in the absence of one such as VEGFA.

What are some potential alternative pathways to initiate endothelial cell
migration and sex-specific vascularization that do not utilize VEGFA?
Cox1/2 pathway
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VEGFA is regulated through increased HIF1A (hypoxia inducible factor 1, alpha subunit)
upregulation during hypoxia. It is possible that the COX pathway through PGE2 upregulates
VEGFA as well as direct upregulation through COX2 (Fig. 2). Postnatal day 30 whole testes
were collected from Sry-Cre;Vegfa−/− conditional knockout mice and compared to controls
for differences in genes within the VEGFA signal transduction pathway using a VEGFA
signal transduction array plate. When the data analyzed with Ingenuity Pathway Analysis
(IPA), the COX1 (PTGS1) constitutively expressed gene was upregulated 5-fold (Sargent,
Spuri Gomes, Essink, Kurz, Pohlmeier, Ferrara, Bouma, McLean, and Cupp; Sargent,
Essink, Bremer, Pohlmeier, and Cupp, unpublished observations). These data indicate that
elimination of VEGFA (in this case in Sertoli cells) may allow for compensatory
mechanisms which regulate other angiogenic factors to allow for normal tissue
development.
Other VEGF ligands
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VEGFB knockout mice are fertile and viable with no apparent phenotype; however, they do
exhibit a subtle cardiac phenotype (Aase et al. 1999). Transcription of the Vegfb gene is not
stimulated by hypoxia or other growth factors, cytokines, etc. VEGFB binds to FLT1 and
NRP1, while VEGFC binds to VEGFR3 and KDR and enhances vasculature within the
lymphatic system. VEGFC is expressed in the heart, placenta, ovary, small intestine and
thyroid gland (Olofsson et al. 1999). In the embryo, it is expressed in regions where
lymphatic vessels sprout from embryonic veins. Similar to VEGFB this gene is not regulated
by hypoxia but interleukin 1 (IL1) and tumor necrosis factor (TNF) can increase VEGFC
(Kukk et al. 1996). VEGFD is expressed in the lung, heart, skeletal muscle, colon and small
intestine. In embryos, VEGFD is most abundant in the lung. Like VEGFC, it binds to both
VEGFR3 and KDR (Olofsson et al. 1999). There have been no reports of VEGFB or
VEGFC present in or involved with testis development, but due to their potential actions
through VEGF receptors, these could be two potential candidates that may function in
VEGFA's absence to initiate sex-specific vascular development.

What about other growth factors that have similar functions to VEGFA that
Author Manuscript

could compensate for sex-specific vascular development?
Platelet Derived Growth Factor
Platelet derived growth factor receptor alpha (PDGFRα) and PDGFRβ are receptors for
PDGF-AA, PDGF-BB, PDGF-CC and PDGF-DD and these receptors are structurally
similar to the VEGFR's (Heldin 2013). PDGFB is expressed in endothelial cells and Pdgfb
and Pdgfrb knockout mice are embryonic lethal during late gestation due to widespread

J Endocrinol. Author manuscript; available in PMC 2016 October 01.

Sargent et al.

Page 16

Author Manuscript

hemorrhaging and capillary dilation (Hellstrom et al. 1999; Leveen et al. 1994; Lindahl et
al. 1997; Soriano 1994). Fetuses appear normal, but the absence of vascular smooth muscle
cells and /or pericytes leads to cardiovascular complications. In the rat, PDGF-AA, PDGFBB and their receptors are expressed in human fetuses (Basciani et al. 2002), and PDGFBB, when inhibited, has been demonstrated to affect vascular development and perturb or
totally inhibit seminiferous cord formation in the mouse (Puglianiello et al. 2004). Inhibitors
to the PDGF-BB signal transduction pathway (PGFR-specific inhibitor Tyrophostin) have
also inhibited seminiferous cord formation in the rat (Uzumcu et al. 2002a). Furthermore,
PDGF has also been identified to work cooperatively with VEGFA in vascular events and
remodeling within the testis (Cool et al. 2011) during the process of sex-specific vascular
development. Thus, PDGF and its receptors may comprise a mechanism where endothelial
migration and seminiferous cord formation occur in the absence of VEGFA isoforms.
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R-spondin homolog
Recently, RSPO1 (R-spondin homolog), which is necessary for ovarian development, has
been shown to induce angiogenesis within the developing testis and to inhibit actions of the
dickkopf homolog 1 (Dkk1) gene which perturbs endothelial branching by inhibiting
PDGFB (Caruso et al. 2015). Interestingly, RSPO1 can rescue DKK1 inhibition of
angiogenesis indicating that perhaps RSPO1 is critical for necessary availability of PDGFB
for endothelial cell branching during testis development. These actions of RSPO1 are
thought to be mediated through beta catenin (CTNNB1) since testes treated in vitro with
RSPO1 exhibit enhanced nuclear translocation of CTNNB1 which will affect gene
expression within the nucleus (Caruso et al. 2015).
VEGF Receptors that bind other ligands
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It is possible that the receptors that VEGFA signals through may elicit effects following
binding by other ligands within the VEGF family to induce endothelial cell migration. An
example of this is the potential for FLT1 to be induced through hypoxia and cooperate with
PGF (Placental Growth Factor to promote pathological angiogenesis that occurs during
diseases and disorder such as pre-eclampsia (Autiero et al. 2003; Hiratsuka et al. 2001).
FLT1 upregulation can be stimulated by hypoxia (Gerber et al. 1997) and has been shown to
activate PGF in VEGF-responsive monocytes which release proangiogenic factors. Further,
FLT1 tyrosine kinase signaling mediates chemotactive macrophage migration in response to
PGF and both VEGF, and PGF promotes macrophage survival during tumor angiogenesis
(Adini et al. 2002; Barleon et al. 1996; Clauss et al. 1996; Hiratsuka et al. 1998; Selvaraj et
al. 2003). Recently macrophage migration was demonstrated to occur during testis
development and the authors implicated that VEGFA was expressed by macrophages and
that vascular development may, thus, be directed by these macrophages (DeFalco et al.
2014). These are intriguing data and may suggest that macrophages derived from the yolk
sac (which are extraembryonic along with primordial germ cells) are critical for sex-specific
vascular development. So the possibility of macrophages directing endothelial cell migration
is a potential mechanism that should be further evaluated.
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Summary
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While there is overwhelming in vitro evidence to support the theory that VEGFA and its
receptors, FLT1, KDR, and NRP1, are critical for sex-specific vascular development which
can allow for seminiferous cord formation, conditional knockout data in mice where
VEGFA was eliminated in Sertoli, Leydig and germ cells do not support this theory.
Because the development of the testis is so critical to the propagation of the species,
suggesting that VEGFA can only be the critical regulator of this process may be somewhat
simplistic. Just as SOX9 has multiple regulators which sustain its expression, there are
potentially many independent angiogenic pathways which contribute to the migration of
endothelial cells to initiate seminiferous cord formation. In this review article, we have
suggested several other pathways which may independently mimic the actions of VEGFA in
supporting endothelial cell migration and development of this quite extraordinary vascular
development within the testis. We, along with others, investigating this area will have many
more years to work on unraveling the complexities of this pathway, to gain a better
understanding of how the testis develops, and paving new avenues for treating infertility
which may be a predictor of male health and lifespan.
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Figure 1.
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Gene expression during testis morphogenesis. Depicted above the timeline is a network
pieced together based on gene and protein interactions in the literature related to sex-specific
vascular development and sexual differentiation. The bottom of the figure depicts different
stages of testis development. PGC = primordial germ cell, SRY = sex determining region of
Chr Y, SXO9 = SRY (sex determining region Y)-box 9, WNT4 = wingless-type MMTV
integration site family, member 4, PGD2 = prostaglandin D2, PDGFR = platelet derived
growth factor receptor, FGF9 = fibroblast growth factor 9, COX = cyclooxygenase 1/2,
VEGFA = vascular endothelial growth factor A.
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Figure 2.

Proposed pathway of prostaglandin synthesis and interaction with the cyclooxygenase
pathways and VEGFA. PLA2 = phospholipase A2, PG = prostaglandin, COX=
cyclooxygenase, VEGFA = vascular endothelial growth factor A.
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Figure 3.
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VEGF receptors which are critical to the actions of VEGFA. Pictured is binding of
angiogenic VEGFA isoforms to either KDR (top right) or FLT1 (top left). Only angiogenic
isoforms of VEGFA bind to NRP1 (top). Antiangiogenic VEGFA isoform binding to either
KDR (bottom left) or FLT1 (bottom right) results in less and different signal transduction
than angiogenic. Antiangiogenic VEGFA isoforms are unable to bind NRP1 (bottom).
Phosphorylation sties are depicted as “P” within a circle. Y = tyrosine, VEGFA = vascular
endothelial growth factor A, KDR = kinase insert domain protein receptor, FLT1 = fms-like
tyrosine kinase 1, NRP1 = neuropilin 1, TSAd = T-cell Specific Adaptor, SRC = Rous
sarcoma oncogene, PI3K = phosphatidylinositol 3-kinase, GRB2 = growth factor receptor
bound protein 2, CDC42 = cell division cycle 42, (p38)MAPK = mitogen-activated protein
kinase, HSP27 = heat shock protein 27, PLCγ = phospholipase C gamma, PKC = protein
kinase C, SHC/SCK = src homology 2 domain-containing transforming protein, SHB = src
homology 2 domain-containing transforming protein B, AKT = thymoma viral protooncogene, eNOS = nitric oxide synthase 3, endothelial cell, FAK = focal adhesion kinase.
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Figure 4.
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VEGFA gene containing all exons and both heparin- and NRP1-binding sites as well as the
canonical stop codons targeted for alternative splicing between either angiogenic or
antiangiogenic isoforms (A). Various rodent angiogenic VEGFA isoforms (B, left) and
antiangiogenic isoforms (B, right) have been identified following alternative splicing. In the
human and bovine, the amino acids numbers differ from rodent. Pictured are the most well
known/studied angiogenic VEGFA isoforms (left, C) and antiangiogenic isoforms (top right,
C). Also depicted is the recently identified VEGFAx that possesses antiangiogenic
properties in humans and bovines (bottom right, C).
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Signal Transduction Inhibitors of VEGFA Signaling and their effects on Rat Embryonic Testis Cord
Formation and Vascular Development in vitro (Data from Bott et al. 2010)
Signal Transduction Pathway

Inhibitor

Effect on Cord
Formation

Effects on Vasculature

PECAM1 Staining

Inhibits KDR

SU1498 (Calbiochem, #572888)

No cord formation

Little vasculature, no
coelomic vessel

10%

Inhibits KDR and FLT1

VEGF-TKI (Calbiochem, #676475)

No cord formation

No vasculature dividing,
no coelomic vessel

10%

Inhibits NRP1

Je11 (Calbiochem, #676494)

No cords/
perturbed cord
formation

Coelomic vessel, some
microvessels, but
reduced density

58%

Inhibits PI3K

LY294002 (Calbiochem, #440202)

Cords perturbed or
swollen

Weak coelomic vessel,
less dense vasculature

54%

VEGFA = vascular endothelial growth factor A
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KDR = kinase insert domain protein receptor
FLT1 = FMS-like tyrosine kinase 1
NRP1 = neuropilin 1
PI3K = phosphatidylinositol 3-kinase
PECAM1 = platelet/endothelial cell adhesion molecule 1
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Effects of Recombinant VEGFA Protein or VEGFAxxxb Antibody on Rat Embrynic Testis Testis Cord
Formation and Vascular Development in vitro (Data from Baltes-Breitwisch et al. 2010)
Recombinant VEGFA Protein

Effect on Cord Formation

Effects on Vasculature

PECAM Staining

VEGFA120

Swollen cords with some perturbed
(R&D Systems, #494-VE)

Thickened coelomic vessel, more
vasculature between cords

157%

VEGFA164

Some cords misshapen or perturbed
(R&D Systems, #564-RV)

Thickened coelomic vessel, more
vasculature between cords that formed

160%

VEGFAxxxb antibody (5 ng/ml)

Swollen or perturbed cords,
misshapen cords (Abcam, #ab14994)

Increased vasculature all throughout testis

195%

VEGFAxxxb antibody (50 ng/ml)

Swollen or perturbed cords,
misshapen cords (Abcam, #ab14994)

Increased vasculature all throughout testis

195%

VEGFA = vascular endothelial growth factor A
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